

Rx Only

NOT FOR OPHTHALMIC USE.

Structural formula:



CLINICAL PHARMACOLOGY

Microbiology

Nystatin acts by binding to sterols in the cell membrane of susceptible species resulting

in a change in membrane permeability and the subsequent leakage of intracellular components. On repeated subculturing with increasing levels of nystatin, *Candida albicans* does not develop resistance to nystatin. Generally, resistance to nystatin does not develop during therapy. However, other species of *Candida* (*C. tropicalis*, *C. guilliermondi*, *C. krusei*, and *C. stellatoidea*) become quite resistant on treatment with nystatin and simultaneously become cross resistant to amphotericin as well. This resistance is lost when the antibiotic is removed.

Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.

INDICATIONS AND USAGE

Nystatin topical powder is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by *Candida albicans* and other susceptible *Candida* species.

Nystatin topical powder is not indicated for systemic, oral, intravaginal or ophthalmic use.

CONTRAINDICATIONS

Nystatin topical powder is contraindicated in patients with a history of hypersensitivity to **any** of its components.

PRECAUTIONS

General

Nystatin topical powder should not be used for the treatment of systemic, oral, intravaginal or ophthalmic infections.

If irritation or sensitization develops, treatment should be discontinued and appropriate measures taken as indicated. It is recommended that KOH smears, cultures, or other diagnostic methods be used to confirm the diagnosis of cutaneous or mucocutaneous candidiasis and to rule out other infection caused by other pathogens.

INFORMATION FOR THE PATIENT

Patients using this medication should receive the following information and instructions:

1. The patient should be instructed to use this medication as directed (including the replacement of missed doses). This medication is not for any disorder other than that for which it is prescribed.
2. Even if symptomatic relief occurs within the first few days of treatment, the patient should be advised not to interrupt or discontinue therapy until the prescribed course of treatment is completed.
3. If symptoms or irritation develop, the patient should be advised to notify the physician promptly.

Laboratory Tests

If there is lack of therapeutic response, KOH smears, cultures, or other diagnostic methods should be repeated.

Carcinogenesis, Mutagenesis, Impairment of Fertility

No long-term animal studies have been performed to evaluate the carcinogenic potential of nystatin. No studies have been performed to determine the mutagenicity of nystatin or its effects on male or female fertility.

Pregnancy

Teratogenic Effects

Category C

Animal reproduction studies have not been conducted with any nystatin topical preparation. It also is not known whether these preparations can cause fetal harm when used by a pregnant woman or can affect reproductive capacity. Nystatin topical powder should be prescribed for a pregnant woman only if the potential benefit to the mother outweighs the potential risk to the fetus.

Nursing Mother

It is not known whether nystatin is excreted in human milk. Caution should be exercised when nystatin is prescribed for a nursing woman.

Pediatric Use

Safety and effectiveness have been established in the pediatric population from birth to 16 years. (See **DOSAGE AND ADMINISTRATION.**)

Geriatric Use

Clinical studies with nystatin topical powder did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently than younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

ADVERSE REACTIONS

The frequency of adverse events reported in patients using nystatin topical powder is less than 0.1%. The more common events that were reported include allergic reactions, burning, itching, rash, eczema, and pain on application. (See **PRECAUTIONS, General.**)

DOSAGE AND ADMINISTRATION

Very moist lesions are best treated with the topical dusting powder.

Adults and Pediatric Patients (Neonates and Older)

Apply to candidal lesions two or three times daily until healing is complete. For fungal infections of the feet caused by *Candida* species, the powder should be dusted on the feet, as well as, in all foot wear.

HOW SUPPLIED

Nystatin topical powder, USP is supplied as 100,000 units nystatin per gram in plastic squeeze bottles:

15 g (NDC 68382-370-01)

30 g (NDC 68382-370-02)

60 g (NDC 68382-370-03)

STORAGE

Store at 20°C to 25°C (68°F to 77°F)[see USP Controlled Room Temperature]; avoid excessive heat (40°C/104°F).

Keep tightly closed.

Manufactured By:

Zydus Lifesciences Ltd.

Baddi, India.

Distributed by:

Zydus Pharmaceuticals USA Inc.

Pennington, NJ 08534

Rev.: 09/22

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 68382-370-01

Nystatin Topical Powder, USP


FOR TOPICAL USE ONLY

100,000 units per gram

Rx Only

15 GRAMS

Zydus



15 g Bottle Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 68382-370-02

Nystatin Topical Powder, USP


FOR TOPICAL USE ONLY

100,000 units per gram

Rx Only

30 GRAMS

Zydus



30 g Bottle Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 68382-370-03

Nystatin Topical Powder, USP

FOR TOPICAL USE ONLY

100,000 units per gram

Rx Only

60 GRAMS

Zydus

The label is for a 30 g bottle of Nystatin Topical Powder, USP. It features a purple header with the NDC number 68382-370-03. The product name is prominently displayed in large black font. Below it, it states 'FOR TOPICAL USE ONLY' and '100,000 units per gram' in a blue box. The Zydus logo is at the bottom left. On the right, there is detailed information including dosage instructions, storage conditions, and manufacturer details. A barcode is located on the left side of the label.

NDC 68382-370-03

**Nystatin
Topical
Powder, USP**

FOR TOPICAL
USE ONLY

100,000
units per gram

zydus

60 GRAMS
Rx only

Each gram contains 100,000 USP
nystatin units dispersed in talc.

Not for Ophthalmic Use.

USUAL DOSAGE: Apply to
affected area 2 or 3 times daily.

Store at 20°C to 25°C (68°F to 77°F).
[See USP Controlled Room
Temperature.]; avoid excessive heat
(40°C/104°F).

Keep this and all drugs out of the
reach of children.

HP/Drugs/MNB/2004/84

Manufactured by:
Zydus Lifesciences Ltd.
Baddi, India

Distributed by:
Zydus Pharmaceuticals (USA) Inc.
Pennington, NJ 08534

XXXXXX
Rev: 10/22

3
N
6838237003
7

60 g Bottle Label

NYSTATIN

nystatin powder

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:68382-370	
Route of Administration	TOPICAL			
Active Ingredient/Active Moiety				
Ingredient Name		Basis of Strength	Strength	
NYSTATIN (UNII: BDF1O1C72E) (NYSTATIN - UNII:BDF1O1C72E)		NYSTATIN	100000 [USP'U] in 1 g	
Inactive Ingredients				
Ingredient Name		Strength		
TALC (UNII: 7SEV7J4R1U)				
Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:68382-370-01	15 g in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	10/06/2021	
2	NDC:68382-370-03	60 g in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	10/06/2021	
3	NDC:68382-370-02	30 g in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	10/06/2021	
Marketing Information				
Marketing Category		Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA		ANDA208581	10/06/2021	

Labeler - Zydus Pharmaceuticals USA Inc. (156861945)

Establishment

Name	Address	ID/FEI	Business Operations
Zydus Lifesciences Limited		677605858	ANALYSIS(68382-370) , MANUFACTURE(68382-370)

Revised: 11/2023

Zydus Pharmaceuticals USA Inc.